Options trading for BrainStorm Cell Therapeutics Inc. (BCLI, Financial) is set to be discontinued effective May 19th. Investors will no longer see BCLI in the options market after this date. This change is part of a broader update involving multiple stocks where certain options will be removed from trading.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Brainstorm Cell Therapeutics Inc (BCLI, Financial) is $14.26 with a high estimate of $22.51 and a low estimate of $6.00. The average target implies an upside of 979.92% from the current price of $1.32. More detailed estimate data can be found on the Brainstorm Cell Therapeutics Inc (BCLI) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Brainstorm Cell Therapeutics Inc's (BCLI, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
BCLI Key Business Developments
Release Date: March 31, 2025
- Research and Development Expenditures: $4.7 million for the year ended December 31, 2024, compared to $10.7 million in 2023.
- General and Administrative Expenses: Approximately $7 million for the year ended December 31, 2024, compared to $10.7 million in 2023.
- Net Loss: Approximately $11.6 million or $2.31 per share for the year ended December 31, 2024, compared to $17.2 million or $6 per share in 2023.
- Cash, Cash Equivalents, and Restricted Cash: Approximately $0.4 million as of December 31, 2024, compared to $1.5 million as of December 31, 2023.
- Warrant Inducement Agreement: Expected to raise approximately $1.64 million in gross proceeds, closing on or about April 1, 2025.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Brainstorm Cell Therapeutics Inc (BCLI, Financial) has secured a special protocol assessment with the FDA, significantly de-risking the regulatory pathway for their NurOwn technology.
- The company is actively negotiating clinical trial agreements with approximately 15 leading clinical centers across the United States, indicating strong interest from renowned ALS clinicians and researchers.
- Brainstorm Cell Therapeutics Inc (BCLI) has partnered with IQVIA, a leading clinical research organization, to ensure efficient execution of their Phase 3b trial.
- The company has contracted with Pluri Inc. for clinical manufacturing, leveraging their expertise in GMP-compliant production, and plans to bring an additional US-based manufacturing center online.
- Brainstorm Cell Therapeutics Inc (BCLI) is exploring multiple funding avenues, including licensing non-core assets and non-dilutive financing opportunities such as grants, to secure necessary funding for the Phase 3b trial.
Negative Points
- The company is facing financial constraints, with cash, cash equivalents, and restricted cash at approximately $0.4 million as of the end of December 2024.
- There are perceived delays in initiating the Phase 3b trial due to the intricate and time-consuming nature of regulatory processes and negotiations with clinical trial sites.
- Brainstorm Cell Therapeutics Inc (BCLI) anticipates needing approximately $20 million to $30 million annually to see the trial to its conclusion, which is challenging given the current market conditions for non-revenue biotech companies.
- The company has implemented salary reductions and periods of unpaid work for its staff to manage financial constraints, indicating significant financial pressure.
- Skepticism remains among analysts and investors regarding the efficacy of NurOwn, despite the company's efforts to address these concerns through trial design and collaboration with key opinion leaders.
